BOSTON ( TheStreet) -- Adam Feuerstein's take on the biotech week that was Oct. 11, 2010: Pfizer ( PFE) buys King Pharmaceuticals ( KG) for $3.6 billion to bolster its pain drug franchise. Pfizer adds new partners through King Buy Alkermes ( ALKS) CEO Richard Pops (@popsalks) breaks company news on Twitter. Bravo! (via @MikeHuckman) The news broken by Pops: Finally, a drug approval in October! Alkermes received FDA clearance to market Vivitrol as a treatment for opioid addiction. Alexza Pharmaceuticals ( ALXA) and Jazz Pharmaceuticals ( JAZZ) not as lucky: FDA denies approval to both of their drugs. Questcor Pharmaceuticals ( QCOR) receives belated FDA approval for Acthar as a treatment for infantile spasms. The week's top-performing sector stocks: Pharmathene ( PIP) (+120%), Molecular Insight Pharmaceuticals ( MIPI) (+65%), Rosetta Genomics ( ROSG) (+60%), SIGA Technologies ( SIGA) (+56%) and King Pharmaceuticals ( KG) (+37%). Johnson & Johnson's ( JNJ) abiraterone boosts survival by four months for patients with advanced prostate cancer. Seattle Genetics ( SGEN) reported a second clinical trial win for the lymphoma drug brentuximab vedotin. This week's Biotech Stock Mailbag: Exact Sciences ( EXAS), Sequenom ( SQNM), Vanda Pharmaceuticals ( VNDA), Delcath Systems ( DCTH), Labopharm ( DDSS), Cadence Pharmaceuticals ( CADX) and Transcept Pharmaceuticals ( TSPT). Forbes' Matt Herper on the fight against drug-resistant germs. Cancer drug analyst and blogger Sally Church spends the week at the European cancer conference known as ESMO. The week's worst-performing sector stocks: Alexza Pharmaceuticals ( ALXA) (-56%), Spherix ( SPEX) (-24%), AspenBio Pharma ( APPY) (-17%), Anadys Pharmaceuticals ( ANDS) (-16%) and ProPhase Labs ( PRPH) (-13%). Cubist Pharmaceuticals ( CBST) reports third quarter Cubicin sales of $154 million, lower than the consensus estimate of $162 million. The company reports higher-than-expected earnings for the quarter on lower operating expenses. The biggest (sore) losers: Arena Pharmaceuticals ( ARNA) investors. Chemist and blogger Derek Lowe takes another skeptical look at the anti-aging claims made about GlaxoSmithKline's resveratrol. Will the withdrawal of Meridia help or hurt other weight-loss pills? (via Pharmalot) Reuters Health editor Ivan Oransky on Geron ( GERN) and its first-ever stem cell study in patients with spinal cord injury. "Scrapers" are scouring web sites looking for patients' personal information. Roche reports weaker-than-expected sales of its three most important drugs -- Avastin, Rituxan and Herceptin. Overall, third quarter revenue fell 7%. ImmunoGen ( IMGN) and Novartis ( NVS) strike a licensing deal to develop cancer drugs based on ImmunoGen's "armed antibody" drug delivery technology. Exelixis ( EXEL) licenses two experimental cancer drugs to Bristol-Myers Squibb ( BMY). Perfect FDA Drug Approval Pickers Halozyme Therapeutics ( HALO) cut 25% of its workforce in a restructuring move. The week in financings: Regeneron Pharmaceuticals ( RGEN) ($175 million), Cytori Therapeutics ( CYTX) ($19 million) and Anadys Pharmaceuticals ( ANDS) ($25 million). FDA doesn't always heed the recommendations offered by its advisory panels. (via @matthewherper) Phase III data on Titan Pharmaceuticals' ( TTNP.OB) implantable addiction drug is published in JAMA. Boehringer Ingelheim drops development of a drug for the controversial disorder known as female sexual dysfunction. Celgene ( CELG) completes acquisition of Abraxis BioScience. --Written by Adam Feuerstein in Boston. >To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org.